Clearly, these studies underscore the need to analyze the role(s) of the AMPK isoforms in the response of breast cancer cells to all antiestrogen treatments, and to determine if selective blockade of AMPKα2 is a viable molecular approach to combat antiestrogen resistance and delay relapse. Here, PRKAA2 is linked to breast carcinoma.